Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium lactis 420
- Development stage
- Unknown
- Lead developer
- International Flavors & Fragrances
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium lactis 420 is a proprietary probiotic strain of the species Bifidobacterium animalis subsp. lactis that has been clinically studied for its effects on weight management and metabolic health. It is believed to support body weight regulation by modulating the gut microbiome and improving intestinal barrier integrity[1][2][4]. Clinical trials have shown that supplementation with this strain can help reduce body fat mass, body weight, waist circumference, and calorie intake in overweight individuals[1][4]. Mechanistically, it may increase levels of Akkermansia muciniphila (a beneficial gut bacterium associated with leanness), reduce markers of inflammation and dysbiosis in the gut mucosa[1][2][4], and improve glucose metabolism—potentially via increased GLP-1 secretion involved in insulin release and satiety signaling[4]. The strain survives gastrointestinal passage and adheres well to human colonic mucus[2].
- Brand names
- UltraFlora ControlHOWARU ShapeLife-Space Shape B420
- Other names
- bifidobacterium lactis 420bifidobacterium animalis subsp. lactis 420b. lactis b-420
Beyond the preview
Go deeper on bifidobacterium lactis 420.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium lactis 420.